ELAN * Stock Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Elanco Animal Health Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$479.28 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 0.93 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELAN * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 2.0% |
| 1Y | 0% | -13.4% | 3.5% |
Return vs Industry: ELAN * exceeded the MX Pharmaceuticals industry which returned -15% over the past year.
Return vs Market: ELAN * underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| ELAN * volatility | |
|---|---|
| ELAN * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in MX Market | 6.0% |
| 10% least volatile stocks in MX Market | 1.9% |
Stable Share Price: ELAN * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ELAN *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1954 | 9,370 | Jeff Simmons | www.elanco.com |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated Fundamentals Summary
| ELAN * fundamental statistics | |
|---|---|
| Market cap | Mex$79.64b |
| Earnings (TTM) | -Mex$449.12m |
| Revenue (TTM) | Mex$76.73b |
1.0x
P/S Ratio-177.3x
P/E RatioIs ELAN * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELAN * income statement (TTM) | |
|---|---|
| Revenue | US$4.44b |
| Cost of Revenue | US$1.90b |
| Gross Profit | US$2.54b |
| Other Expenses | US$2.57b |
| Earnings | -US$26.00m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.053 |
| Gross Margin | 57.27% |
| Net Profit Margin | -0.59% |
| Debt/Equity Ratio | 80.6% |
How did ELAN * perform over the long term?
See historical performance and comparison